~ The Company Remains Focused on Completing the LOGICS Study and Submitting a New Drug Application (NDA) for RECORLEV™ (levoketoconazole), While Ensuring Continued Growth and Profitability of KEVEYIS® (dichlorphenamide) and Serving the Unmet Needs of the Primary Periodic Paralysis Community ~ ... read more

Oslo, Norway, 13 November 2019   Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the third quarter 2019 on Tuesday, 19 November 2019. A presentation by Nordic Nanovector's senior management team will take place at 8:30am CET at: Thon Hotel Vik... read more

2019-11-13 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, THE UNITED KINGDOM, CANADA, HONGKONG, JAPAN, SWITZERLAND, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE THE PUBLICATION, DISTRIBUTION OR RE... read more

Lund, Sweden, 16:00 CET, November 12 2019BONESUPPORT™ an emerging leader in orthobiologics for the management of bone injuries, announces changes in its leadership team that will take place November 18, 2019. Fergus MacLeod starts in the position as the company's General Manager & Executive... read more

DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announc... read more